source
- Capricor sues Nippon Shinyaku over Duchenne drug 'pricing flaw' and launch prepCapricor Therapeutics said Thursday it has filed a lawsuit against Nippon Shinyaku over a distribution and commercialization agreement for deramiocel, a cell therapy candidate for Duchenne muscular…Endpoints · 2mo ago↗ source
- Odyssey raises more than $300M as biotech goes publicOdyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night. Odyssey began trading on the Nasdaq on Friday. The bio…Endpoints · 2mo ago↗ source
- Odyssey, on second try, snags $279M in an IPOAfter withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even higher through a concu…